Table 1.
Demographic and clinical baseline characteristics for the subset of patients newly initiated on basal insulin with a 12-month follow-up
| Hypoglycemia cohort (n = 2495) | No hypoglycemia cohort (n = 53,113) | P value | |
|---|---|---|---|
| Age, mean (SD), years | 55.6 (13.2) | 54.2 (11.8) | <0.001 |
| ≥65 years [n (%)] | 585 (23.5) | 8692 (16.4) | <0.001 |
| Female [n (%)] | 1135 (45.5) | 23,786 (44.8) | 0.488 |
| CCI score, mean (SD) | 1.63 (2.11) | 1.01 (1.70) | <0.001 |
| Hypertension [n (%)] | 1866 (74.8) | 38,464 (72.4) | <0.010 |
| Hyperlipidemia [n (%)] | 1605 (64.3) | 36,446 (68.6) | <0.001 |
| Mental illness [n (%)] | 718 (28.8) | 11,823 (22.3) | <0.001 |
| Neuropathy [n (%)] | 691 (27.7) | 6621 (12.5) | <0.001 |
| Chronic obstructive pulmonary disease [n (%)] | 487 (19.5) | 8078 (15.2) | <0.001 |
| Renal disease [n (%)] | 438 (17.6) | 4763 (9.0) | <0.001 |
| Nephropathy [n (%)] | 280 (11.2) | 3194 (6.0) | <0.001 |
| Retinopathy [n (%)] | 417 (16.7) | 6464 (12.2) | <0.001 |
| Congestive heart failure [n (%)] | 413 (16.6) | 5054 (9.5) | <0.001 |
| Peripheral vascular disease [n (%)] | 373 (15.0) | 4281 (8.1) | <0.001 |
| Cerebrovascular disease [n (%)] | 338 (13.6) | 4259 (8.0) | <0.001 |
| Any baseline hypoglycemia [n (%)] | 691 (27.7) | 2402 (4.5) | <0.001 |
| Number of OADs, mean (SD) | 1.40 (1.26) | 1.65 (1.24) | <0.001 |
| Baseline SU use [n (%)] | 1148 (46.0) | 27,055 (50.9) | <0.001 |
CCI Charlson comorbidity index, OAD oral antidiabetes drug, SU sulfonylurea, SD standard deviation